Clinical Trials

Advancing diversified GLP-1-based treatments for obesity and overweight

At Kailera we are committed to developing treatment options for people living with obesity and overweight. We are focused exclusively on obesity because this chronic, progressive and debilitating disease can result in a significant negative impact on overall health and quality of life. People with obesity and overweight have a broad range of needs and preferences, and not all these needs are addressed by currently available therapies. With this obesity-first focus, we have built a pipeline designed to provide options for people living with obesity no matter where they are in their treatment journey.
Program
Overview
Clinical Program

Program

Ribupatide (KAI-9531)

Indication

Obesity

Study Name

KaiNETIC

Phase/Status

Phase 3

Overview

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials to evaluate weekly doses of up to 10 mg of ribupatide (KAI-9531) administered by subcutaneous injection over 76 weeks:

    • KaiNETIC-1 (NCT07284875): target enrollment of 1,800 adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with a comorbidity, excluding type 2 diabetes.
    • KaiNETIC-2 (NCT07284901): target enrollment of 1,700 adults with a BMI of 27 kg/m2 or greater with type 2 diabetes.
    • KaiNETIC-3 (NCT07284979): target enrollment of 1,200 adults with a BMI of 35 kg/m2 or greater and without type 2 diabetes. This trial will include an arm that will be randomized to open-label semaglutide 2.4 mg subcutaneous weekly injection.

Learn more at kaineticstudies.com.

Kailera Expanded Access Policy

At this time, Kailera does not provide its investigational medicines outside of clinical trials. Our ongoing clinical trials can be found by visiting clinicaltrials.gov and searching for Kailera Therapeutics. If you are interested in learning whether enrollment in a clinical trial is an option for you or someone you know, please consult with your treating physician, who can contact us as needed with questions.

If you are a healthcare provider who is interested in learning more about our investigational therapies or clinical trials, please submit a request to [email protected].